Aduhelm’s effectiveness is questionable. In a sensible move, Medicare recognizes this.
Forbes post, “The FDA Approves The Alzheimer’s Drug Aducanumab — And Reminds Us Of The Herculean Task Of Medicare Reform”
How willing are we to say “no” to more spending and more questionably-effective drugs?
Forbes post, “Can We Fix ‘The Price We Pay’ For Medicare? A New Book Shows Some Ways Forward”
What can we do about Medicare costs? A lot – according to Makary’s book.